{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:27:36Z","timestamp":1772774856341,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T00:00:00Z","timestamp":1404864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s11030-014-9532-8","type":"journal-article","created":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T13:57:53Z","timestamp":1404827873000},"page":"745-757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A green four-component synthesis of zwitterionic alkyl\/benzyl pyrazolyl barbiturates and their photophysical studies"],"prefix":"10.1007","volume":"18","author":[{"given":"Manisha","family":"Bihani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranjal P.","family":"Bora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghanashyam","family":"Bez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Askari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,9]]},"reference":[{"key":"9532_CR1","doi-asserted-by":"crossref","DOI":"10.1002\/3527605118","volume-title":"Bienaym\u00e9 H (2005) Multicomponent reaction","author":"J Zhu","year":"2005","unstructured":"Zhu J (2005) Bienaym\u00e9 H (2005) Multicomponent reaction. Weinheim, Germany, Wiley- VCH"},{"key":"9532_CR2","doi-asserted-by":"crossref","unstructured":"Tietze LF, Brasche G, Gericke K (2006) Domino reactions in organic synthesis. Eds. Wiley-VCH: Weinheim, Germany","DOI":"10.1002\/9783527609925"},{"key":"9532_CR3","unstructured":"Domling U, Ugi I (2000) Multicomponent reactions with isocyanides. Angew Chem Int Ed 39:3168\u20133210. doi: 10.1002\/1521-3773(20000915)"},{"key":"9532_CR4","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1016\/j.tetlet.2012.07.073","volume":"53","author":"MR Rohman","year":"2012","unstructured":"Rohman MR, Mecadon H, Khan AT, Myrboh B (2012) Synthesis of important $$\\beta $$ \u03b2 -functionalized 5-methyl-1 $$H$$ H -pyrazol-3-ol derivatives in the presence of $$\\gamma $$ \u03b3 -alumina catalyst in aqueous medium. Tetrahedron Lett 53:5261\u20135264. doi: 10.1016\/j.tetlet.2012.07.073","journal-title":"Tetrahedron Lett"},{"key":"9532_CR5","doi-asserted-by":"crossref","first-page":"6834","DOI":"10.1016\/j.tetlet.2012.10.025","volume":"53","author":"SHS Azzam","year":"2012","unstructured":"Azzam SHS, Pasha MA (2012) Simple and efficient protocol for the synthesis of novel dihydro-1 $$H$$ H -pyrano[2,3- $$c$$ c ]pyrazol-6-ones via a one-pot four-component reaction. Tetrahedron Lett 53:6834\u20136837. doi: 10.1016\/j.tetlet.2012.10.025","journal-title":"Tetrahedron Lett"},{"key":"9532_CR6","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2174\/157017812803521135","volume":"9","author":"K Ablajan","year":"2012","unstructured":"Ablajan K, Liju W, Tuoheti A, Kelim Y (2012) An efficient four-component, one-pot synthesis of 6-Amino-4-Aryl-3- Methyl-2,4-Dihydropyrano[2,3-C]Pyrazole-5-Carbonitriles under phase- transfer catalyst. Lett Org Chem 9:639\u2013643. doi: 10.2174\/157017812803521135","journal-title":"Lett Org Chem"},{"key":"9532_CR7","first-page":"125","volume":"1","author":"F Franciso","year":"2005","unstructured":"Franciso F, Govianni G, Franciso R (2005) Reverse regioselection in the synthesis of spiropyrazolobarbiturates using C-Br and C-H nitrilimines. Synlett 1:125\u2013126. doi: 10.1055\/s-2004-836046","journal-title":"Synlett"},{"key":"9532_CR8","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1021\/jm00120a002","volume":"31","author":"BE Evans","year":"1998","unstructured":"Evans BE, Rittle KE, Bock MG, DiPardo RM, Freidinger RM, Whitter WL, Lundell GF, Veber DF, Anderson PSR, Chang SL, Lotti VJ, Cerino DJ, Chen TB, Kling PJ, Kunkel KA, Springer JP, Hirshfield J (1998) Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 31:2235\u20132346. doi: 10.1021\/jm00120a002","journal-title":"J Med Chem"},{"key":"9532_CR9","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2174\/0929867053507388","volume":"12","author":"J Poupaert","year":"2005","unstructured":"Poupaert J, Carato P, Colacino E (2005) 2(3H)-Benzoxazolone and bioisosters as \u201dprivileged scaffold\u201d in the design of pharmacological probes. Curr Med Chem 12:877\u2013885. doi: 10.2174\/0929867053507388","journal-title":"Curr Med Chem"},{"key":"9532_CR10","doi-asserted-by":"crossref","unstructured":"Brunton LL, Lazo JS, Parker KL, Buxton I, Blumenthal D (2006) Goodman and Gilman\u2019s The pharmacological basis of therapeutics. 11th eds, The McGraw- Hill Companies Inc","DOI":"10.1345\/aph.1G685"},{"key":"9532_CR11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2165\/00003495-197509060-00004","volume":"9","author":"MW Johns","year":"1975","unstructured":"Johns MW (1975) Sleep and hypnotic drugs. Drugs 9:448\u2013478. doi: 10.2165\/00003495-197509060-00004","journal-title":"Drugs"},{"key":"9532_CR12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1755-5949.2008.00073.x","volume":"15","author":"C Uhlmann","year":"2009","unstructured":"Uhlmann C, Froscher W (2009) Low risk of development of substance dependence for barbiturates and clobazam prescribed as antiepileptic drugs: results from a questionnaire study. CNS Neurosci Ther 15:24\u201331. doi: 10.1111\/j.1755-5949.2008.00073.x","journal-title":"CNS Neurosci Ther"},{"key":"9532_CR13","unstructured":"Olin BR (1993) Central nervous system drugs, sedatives and hypnotics, barbiturates. Facts and Comparisons, In Facts and Comparisons Drug Information, St. Louis, MO, p 1398"},{"key":"9532_CR14","first-page":"565","volume":"8","author":"D Sriram","year":"2005","unstructured":"Sriram D, Bal TR, Yogeeswari P (2005) Aminopyrimidinimino isatin analogues: Design of novel nonnucleoside HIV-1 reverse transcriptase inhibitors with broadspectrum chemotherapeutic properties. J Pharm Pharmaceut Sci 8:565\u2013577. doi: 10.1016\/j.jcis.2004.09.015","journal-title":"J Pharm Pharmaceut Sci"},{"key":"9532_CR15","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1515\/BC.2001.159","volume":"382","author":"F Grams","year":"2001","unstructured":"Grams F, Brandstetter H, DAl\u00f2 S, Geppert D, Krell H-W, Leinert H, Livi V, Menta E, Oliva A, Zimmermann G (2001) Pyrimidine-2,4,6-Triones: a new effective and selective class of matrix metalloproteinase inhibitors. Biol Chem 382:1277\u20131285. doi: 10.1515\/BC.2001.159","journal-title":"Biol Chem"},{"key":"9532_CR16","unstructured":"Liu M, Cao D, Russell R, Handschumacher RE, Pizzorno G (1998) Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. Cancer Res 58:5418\u2013 5424"},{"key":"9532_CR17","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2174\/092986730609220401153113","volume":"6","author":"PG Goekjian","year":"1999","unstructured":"Goekjian PG, Jirousek MR (1999) Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. Curr Med Chem 6:877\u2013903","journal-title":"Curr Med Chem"},{"key":"9532_CR18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/jb\/mvq147","volume":"149","author":"P Gruber","year":"2011","unstructured":"Gruber P, Rechfeld F, Kirchmair J, Hauser N, Boehler M, Garczarczyk D, Langer T, Hofmann J (2011) Barbituric acid derivative BAS 02104951 inhibits PKC $$\\upvarepsilon $$ \u03b5 , PKC $$\\upeta $$ \u03b7 , PKC $$\\upvarepsilon $$ \u03b5 \/RACK2 interaction, Elk-1 phosphorylation in HeLa and PKC $$\\upvarepsilon $$ \u03b5 and $$\\upeta $$ \u03b7 translocation in PC3 cells following TPA-induction. J Biochem 149:331\u2013336. doi: 10.1093\/jb\/mvq147","journal-title":"J Biochem"},{"key":"9532_CR19","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1016\/j.bmcl.2011.10.055","volume":"21","author":"R Tripathy","year":"2011","unstructured":"Tripathy R, McHugh RJ, Ghose AK, Ott GR, Angeles TS, Albom MS, Huang Z, Aimone LD, Cheng M, Dorsey BD (2011) Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group. Bioorg Med Chem Lett 21:7261\u20137264. doi: 10.1016\/j.bmcl.2011.10.055","journal-title":"Bioorg Med Chem Lett"},{"key":"9532_CR20","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1021\/jm201331s","volume":"55","author":"L Liu","year":"2012","unstructured":"Liu L, Norman MH, Lee M, Xi N, Siegmund A, Boezio AA, Booker S, Choquette D, D\u2019Angelo ND, Germain J, Yang K, Yang Y, Zhang Y, Bellon SF, Whittington DA, Harmange J-C, Dominguez C, Kim T-S, Dussault I (2012) Structure-based design of novel class ii c-met inhibitors: 2. sar and kinase selectivity profiles of the pyrazolone series. J Med Chem 55:1868\u20131897. doi: 10.1021\/jm201331s","journal-title":"J Med Chem"},{"key":"9532_CR21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bmcl.2009.10.108","volume":"20","author":"K Guckian","year":"2010","unstructured":"Guckian K, Carter MBE, Lin Y-S, Choi M, Sun L, Boriack-Sjodin PA, Chuaqui C, Lane B, Cheung K, Ling L, Lee W-C (2010) Pyrazolone based TGFbetaR1 kinase inhibitors. Bioorg Med Chem Lett 20:326\u2013329. doi: 10.1016\/j.bmcl.2009.10.108","journal-title":"Bioorg Med Chem Lett"},{"key":"9532_CR22","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.bmcl.2006.12.054","volume":"17","author":"R Tripathy","year":"2007","unstructured":"Tripathy R, Ghose A, Singh J, Bacon ER, Angeles TS, Yang SX, Albom MS, Aimone LD, Herman JL, Mallamo JP (2007) An easy direct arylation of 5-pyrazolones. Bioorg Med Chem Lett 17:1793\u20131798. doi: 10.1016\/j.bmcl.2006.12.054","journal-title":"Bioorg Med Chem Lett"},{"key":"9532_CR23","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1016\/j.bmcl.2007.06.036","volume":"17","author":"NC Ray","year":"2007","unstructured":"Ray NC, Clark RD, Clark DE, Williams K, Hickin HG, Crackett PH, Dyke HJ, Lockey PM, Wong M, Devos R, White A, Belanoff JK (2007) Discovery and optimization of novel, non-steroidal glucocorticoid receptor modulators. Bioorg Med Chem Lett 17:4901\u20134905. doi: 10.1016\/j.bmcl.2007.06.036","journal-title":"Bioorg Med Chem Lett"},{"key":"9532_CR24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/0006-2952(93)90477-E","volume":"30","author":"FNM Naguib","year":"1993","unstructured":"Naguib FNM, Levesque DL, Wang E-C, Panzica RP, El kouni MH (1993) 5-Benzylbarbituric acid derivatives, potent and specific inhibitors of uridine phosphorylase. Biochem Pharmacol 30:1273\u20131283. doi: 10.1016\/0006-2952(93)90477-E","journal-title":"Biochem Pharmacol"},{"key":"9532_CR25","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/jhet.5570300537","volume":"30","author":"DL Levesque","year":"1993","unstructured":"Levesque DL, Wang E-C, Wei D-C, Kouni EMH, Naguib FNM (1993) Synthesis of a new class of uridine phosphorylase inhibitors. J Heterocycl Chem 30:1399\u20131404. doi: 10.1002\/jhet.5570300537","journal-title":"J Heterocycl Chem"},{"key":"9532_CR26","unstructured":"Oliva A, De Cillis G, Grams F, Livi V, Zimmerman G, Menta E, Krell HW (2002) Barbituric acid derivatives with antimetastatic and antitumor activity. US Patent 6, 335, 332, B1"},{"issue":"A1","key":"9532_CR27","first-page":"19990527","volume":"9925699","author":"RI Ashkinazi","year":"1999","unstructured":"Ashkinazi RI (1999) Salts of 5,5\u2019-arylidenebis[barbituric acids] and 5,5\u2019-arylidenebis[2-thiobarbituric acids] having antibacterial, antichlamydial, antiviral and immunomodulating activity. PCT Int Patent WO 9925699(A1):19990527","journal-title":"PCT Int Patent WO"},{"key":"9532_CR28","unstructured":"Neumann DM, Jursic BS, Morgan LR (2003) Design, synthesis, and spectroscopic analysis of potential anticancer compounds exhibiting immune modulating properties. Abstracts of Papers, $$225^{{\\rm th}}$$ 225 th ACS National Meeting, New Orleans, LA, US, 2003"},{"issue":"A1","key":"9532_CR29","first-page":"19981230","volume":"9858925","author":"A Oliva","year":"1998","unstructured":"Oliva A, De Cillis G, Grams F, Livi V, Zimmermann G, Menta E, Krell H-W (1998) Preparation of barbituric acid derivatives with antimetastatic and antitumor activity. PCT Int Appl WO 9858925(A1):19981230","journal-title":"PCT Int Appl WO"},{"key":"9532_CR30","unstructured":"Nelson DL, Cox M M (2008) Lehninger Principles of Biochemistry, $$5^{{\\rm th}}$$ 5 th ed, Macmillan"},{"key":"9532_CR31","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1021\/jm3007992","volume":"55","author":"K Maz\u00e1k","year":"2012","unstructured":"Maz\u00e1k K, Nosz\u00e1l B (2012) Zwitterions can be predominant in membrane penetration of drugs: experimental proof. J Med Chem 55:6942\u20136947. doi: 10.1021\/jm3007992","journal-title":"J Med Chem"},{"key":"9532_CR32","doi-asserted-by":"crossref","unstructured":"Zimmnitsky DS, Yurkshtovich TL, Bychkovsky PM (2006) Adsorption of zwitterionic drugs onto oxidized cellulose. J Colloid Interface Sci 295, 33\u201340. doi: 10.1016\/j.jcis.2005.07.058","DOI":"10.1016\/j.jcis.2005.07.058"},{"key":"9532_CR33","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.bbamem.2006.07.002","volume":"1758","author":"T Hirano","year":"2006","unstructured":"Hirano T, Yasuda S, Osaka Y, Kobayashi M, Itagaki S, Iseki K (2006) Mechanism of the inhibitory effect of zwitterionic drugs (levofloxacin and grepafloxacin) on carnitine transporter (OCTN2) in Caco-2 cells. Biochim Biophys Acta 1758:1743\u20131750. doi: 10.1016\/j.bbamem.2006.07.002","journal-title":"Biochim Biophys Acta"},{"key":"9532_CR34","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/adma.200901407","volume":"22","author":"SY Jiang","year":"2010","unstructured":"Jiang SY, Cao ZQ (2010) Ultralow-fouling, functionalizable, and hydrolyzable zwitterionic materials and their derivatives for biological applications. Adv Mater 22:920\u2013932. doi: 10.1002\/adma.200901407","journal-title":"Adv Mater"},{"key":"9532_CR35","doi-asserted-by":"crossref","unstructured":"Cao ZQ, Yu QM, Xue H, Cheng G, Jiang SY (2010) Nanoparticles for drug delivery prepared from amphiphilic plga zwitterionic block copolymers with sharp contrast in polarity between two blocks. Angew Chem Int Ed 49:3771\u20133776. doi: 10.1002\/anie.200907079","DOI":"10.1002\/anie.200907079"},{"key":"9532_CR36","doi-asserted-by":"crossref","first-page":"e24374","DOI":"10.1371\/journal.pone.0024374","volume":"6","author":"RR Arvizo","year":"2011","unstructured":"Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, Robertson JD, Rotello VM, Reid JM, Mukherjee P (2011) Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One 6:e24374. doi: 10.1371\/journal.pone.0024374","journal-title":"PLoS One"},{"key":"9532_CR37","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1021\/cr9601019","volume":"97","author":"A Pagliara","year":"1997","unstructured":"Pagliara A, Carrupt PA, Caron G, Gaillard P, Testa B (1997) Lipophilicity Profiles of Ampholytes. Chem Rev 97:3385\u20133400. doi: 10.1021\/cr9601019","journal-title":"Chem Rev"},{"key":"9532_CR38","doi-asserted-by":"crossref","first-page":"10163","DOI":"10.1021\/jp204424w","volume":"115","author":"NS Moyon","year":"2011","unstructured":"Moyon NS, Mitra S (2011) Luminol Fluorescence Quenching in Biomimicking Environments: Sequestration of Fluorophore in Hydrophobic Domain. J Phys Chem B 115:10163\u201310172. doi: 10.1021\/jp204424w","journal-title":"J Phys Chem B"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-014-9532-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11030-014-9532-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-014-9532-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T16:40:24Z","timestamp":1649608824000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11030-014-9532-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,9]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["9532"],"URL":"https:\/\/doi.org\/10.1007\/s11030-014-9532-8","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,9]]}}}